Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Spartaject busulfan to enter phase I

April 5, 1996

FDA approves expanded labeling for Ethyol

March 15, 1996

Multidrug resistance modulator from Pfizer

March 15, 1996

Xenova to evaluate MDR modulator in phase I

March 15, 1996

MethylGene established to study antisense drugs for cancer indications

March 15, 1996

Eisai describes antitumor sulfonamide

March 15, 1996

OM-174 shows in vivo antitumor activity

March 15, 1996

Glaxo Wellcome reports antitumor drugs

March 15, 1996

Marimastat enters phase II in U.S.

March 15, 1996

Techniclone establishes distribution agreement for Oncolym

March 15, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...